

**Freedom of Information Request**

**Ref: 21-077**

22 February 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some the information you are requesting

**Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:**

- Atezolizumab - 6
- Carboplatin with Gemcitabine - 8
- Carboplatin with Paclitaxel - 0
- Carboplatin single or in any other combination - 0
- Cisplatin with Gemcitabine - 10
- Cisplatin single or in any other combination - 0
- Nivolumab - 0
- MVAC with G-CSF - 0
- Pembrolizumab - 2
- Any other regimen including Paclitaxel - 0
- Any other chemo regimen - 0
- Other active systemic anti-cancer therapy [please state] Avelumab - 4
- Palliative care only – palliative care team have previously advised unable to supply on similar FOIs due to the vast number of ways patient can be referred to palliative care services some of which bypass UHB entirely.

**Q2. Could you please provide the total number of patients with any treatment in the last three months for:**

- **Total non-small cell lung cancer (NSCLC)**
- **BRAF+ non-small cell lung cancer (NSCLC)**

It is not possible to split data down as required by histology as we do not hold the information in a reportable format.

**Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:**

- Afatinib - 3
- Alectinib - 11
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 0
- Atezolizumab monotherapy - 6
- Bevacizumab - 0
- Brigatinib - 2
- Ceritinib - 0
- Crizotinib - 0
- Dacomitinib - 0
- Dabrafenib with Trametinib - 1
- Docetaxel - 1
- Durvalumab - 8
- Erlotinib - 3
- Gefitinib - 0
- Gemcitabine - 0
- Nintedanib with Docetaxel - 6
- Nivolumab - 2
- Osimertinib - 7
- Paclitaxel - 0
- Pembrolizumab chemo in combination - 25
- Pembrolizumab monotherapy - 33
- Pemetrexed with Carboplatin - 8
- Pemetrexed with Cisplatin - 0
- Vinorelbine and cisplatin/carboplatin - 12

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance  
 University Hospitals Bristol and Weston NHS Foundation Trust  
 Trust Headquarters  
 Marlborough Street  
 Bristol  
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be

contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**